Live
Suven Life Sciences has received 2 product patent, 1 from Eurasia and other from Norway, related to the new chemical entities (NCEs), for the treatment of disorders associated with Neurodegenerative diseases.
These patents will be valid till 2034 and 2026 respectively. The patents include the class of selective 5-HT6 compounds and are being developed as therapeutic agents. They are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.
Further, as per CEO of Suven, Venkat Jasti, “We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally.”
